Post bogus job announcements to collect resumes with no positions available. Do not count on them. Then play lowball, particularly if overseas office assignment. They do not provide recent software tools. You may end up temporarily only.
Micromanagment and a sense of distrust. Backstabbing aggressive team mates. Culture of not feeling free to speak up with different opinions. Punitive managers.
To the Post on Ultragenyx:
No surprise, Ultragenyx has Biomarin roots therefore the bad management practices. leadership it is not, but manipulators who hijacked upper positions taking care of their careers repeating the all worn meaningless phrases from the leadership training fads. Biomarin management misbehaved badly during layoffs enlisting the Irish office into chainsaw work on the US soil. Currently due to biopharma under layoffs stress, they think they are free to do anything!
More responsibilities keep being tossed on while reduction of headcounts and very minimal annual salary increase (~ 3%), meanwhile no accolade or gratitude from leadership and peers from different functions for all the extra hard work I did to benefit you or other functions. All talk and no walk from senior leadership. It's a closed door; sr leadership doesn't even acknowledge and say hi.
Gilead has one of the highest revenues per employee, so it can afford mismanagement, bad strategies, dei, Kite drag, and other wasteful policies. Who pays for this? Patients, taxpayers and all thru insurance premiums.
Sartorius develops and offers products and solutions following their own ways, that are not always the best, or following what the customers want or need.
Stock seems to be very volatile going up or down a few %. This might be result of company instability and related poor management and bad strategy. But there could be another reason, managing to cause such stock price swings, so the founders, big investors and cronies can profit from these price swings. SEC may look closer at this manipulation.
New CEO task by Roche was to bring the stock price below $60, so Roche could consider an acquisition. It is getting there.
Even if Roche offers some premium, the investors would lose badly in comparison to the past valuation. The CEO has been busy on this, not on improving a quality of management team.
Gilead has announced more than 100 person layoff coming, this time from the HQ location.
Streamlining ahead of a new administration, or as usual, a result of internal chaos and turmoil?
More layoffs would come in 2025.
layoff of 72, a small number comparing to company size, but be one of these.
Another proof how incompetent the pharma management is. Strategy, what strategy? Firstly they create a hype, hire many and then, oops!
Roche feels Genentech is like a cancer on a body of Roche. Outlived its usefulness and is going by inertia. Many opportunists hang around and look busy. This is natural feed for toxic work environment. Next year Roche will make some move in this regard.
MariTide and bone loss:
Get ready for purge, there is additional excuse.
Although it was "only" Level 1 trials.
Amgen never misses opportunity to purge ranks, though.
Astria sounds better than Catab.
We just got a person to help us who was a failure in Pfizer and a failure in Moderna. Hope he will not fail all of us.
Poorly managed with no consequences to management. If taking a wrong direction, staying there for too long. Example can be membrane chromatography. At the same time wasting good opportunities. Strange selection of managers making strange decisions.
New layoff lists are being prepared. Make sure you know whether your name is on a list. Also check who can be influential in this process and who is responsible for singling you out.
